In response to these challenges, tocilizumab, an IL-6 monoclonal antibody, is commonly used to treat CRS (53), and IFN-γ is being explored as a potential new target for heart disease caused by CRS or CAR-T therapy. Here, IFNG is linked to congenital rubella syndrome.